Opticyte
Opticyte is a medical device company developing a noninvasive monitoring system that measures both cellular oxygenation and arterial blood oxygen saturation in real time. The company focuses on earlier detection of organ hypoxia to inform clinical decision-making in acute care settings and emphasizes reducing skin-tone bias in optical oxygen measurements. Opticyte was spun out of an academic laboratory, has received NIH SBIR/STTR funding, and has engaged with US regulatory pathways for novel devices.
Industries
Nr. of Employees
small (1-50)
Products
Noninvasive cellular and arterial oxygen monitor
A bedside monitoring device that measures cellular (muscle) oxygenation and arterial blood oxygen saturation in real time using visible–near-infrared optical spectroscopy and algorithmic analysis.
Cell O2
A medical device using proprietary advanced algorithms and tailored optical spectroscopy technology to measure and detect low oxygen levels in cells to prevent organ failure, particularly targeting sepsis care.
Cell O2 technology
A pulse oximetry technology recognized by the FDA for significantly improving the accuracy of oxygen saturation measurements in patients with dark skin tones.
Opticyte VitalO2
A monitor designed to measure oxygen levels inside the body's cells, providing early warning signs of oxygen deficiency to help prevent organ failure, especially in sepsis patients.
Opticyte VitalO₂
A device that measures cellular oxygenation continuously and noninvasively to help hospitals monitor, diagnose, and treat critically ill patients, enabling early detection of sepsis, trauma, and respiratory failure.
Noninvasive cellular and arterial oxygen monitor
A bedside monitoring device that measures cellular (muscle) oxygenation and arterial blood oxygen saturation in real time using visible–near-infrared optical spectroscopy and algorithmic analysis.
Cell O2
A medical device using proprietary advanced algorithms and tailored optical spectroscopy technology to measure and detect low oxygen levels in cells to prevent organ failure, particularly targeting sepsis care.
Cell O2 technology
A pulse oximetry technology recognized by the FDA for significantly improving the accuracy of oxygen saturation measurements in patients with dark skin tones.
Opticyte VitalO2
A monitor designed to measure oxygen levels inside the body's cells, providing early warning signs of oxygen deficiency to help prevent organ failure, especially in sepsis patients.
Opticyte VitalO₂
A device that measures cellular oxygenation continuously and noninvasively to help hospitals monitor, diagnose, and treat critically ill patients, enabling early detection of sepsis, trauma, and respiratory failure.
Services
Engagement with qualified investors, clinical partners, and development collaborators for device commercialization and clinical studies.
Collaboration with academic and clinical investigators and participation in scientific conferences to support validation and dissemination of device research.
Engagement with qualified investors, clinical partners, and development collaborators for device commercialization and clinical studies.
Collaboration with academic and clinical investigators and participation in scientific conferences to support validation and dissemination of device research.
Expertise Areas
- Noninvasive optical tissue oximetry
- Clinical monitoring for acute care (ED/ICU/OR)
- Medical device development and productization
- Regulatory strategy for novel medical devices (FDA interactions, De Novo)
Key Technologies
- Visible–near-infrared spectroscopy (500–800 nm)
- Noninvasive optical oximetry
- Pulse oximetry (SpO2) measurement
- Machine learning for spectral analysis
News & Updates
Company sponsorship and participation in a sepsis-focused symposium.
Company representative served as a featured speaker at a sepsis symposium.
Company CEO presented at a major critical care conference.
Received FDA Breakthrough Device Designation for a patient monitor that measures cellular oxygenation to detect organ failure.
Received a second FDA Breakthrough Device Designation.
Raised approximately $4.6 million in non-dilutive and angel funding to support development and testing of a cellular oxygen monitor.
Company sponsorship and participation in a sepsis-focused symposium.
Company representative served as a featured speaker at a sepsis symposium.
Company CEO presented at a major critical care conference.
Received FDA Breakthrough Device Designation for a patient monitor that measures cellular oxygenation to detect organ failure.
Received a second FDA Breakthrough Device Designation.
Raised approximately $4.6 million in non-dilutive and angel funding to support development and testing of a cellular oxygen monitor.